Houston Oncology Summit: Oppenheimer analysts Jeff Jones and Jay Olson talk radiopharmaceuticals and antibody-drug conjugates

blonca9
Sep 26, 2024
1 min read

Jeff Jones notes how radioisotopes are being added to more than just antibodies, and calls out upcoming data from Perspective Therapeutics. Then, Jay Olson highlights ADC targets to watch while highlighting Bicycle and Sutro.

Brought to you by:

Recent Posts

See All

Stanford professor James Zou and his team created a virtual lab with AI scientists - they designed nanobodies for a COVID variant

William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron

AI News: While most AI in healthcare is aimed at helping physicians better diagnose and treat disease, CureWise is built for patients to help understand their conditions and ask the right questions

Houston Oncology Summit: Oppenheimer analysts Jeff Jones and Jay Olson talk radiopharmaceuticals and antibody-drug conjugates

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight